
NY-ESO 1 89-103, EFYLAMPFATPMEAE
Description
About NY-ESO 1 89-103, EFYLAMPFATPMEAE
The Human Cancer/testis antigen (NY-ESO) 1 Peptide (IEDB: 2232660) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Cancer/testis antigen (NY-ESO) Peptide, H-EFYLAMPFATPMEAE-OH (Uniprot: P78358 aa: 89-103) from JPT is produced under strict quality control and quality management.
NY-ESO 1 89-103, EFYLAMPFATPMEAE - Specifications
- Peptide sequence: H-EFYLAMPFATPMEAE-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Adenocarcinoma, Gastric cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for NY-ESO 1 89-103, EFYLAMPFATPMEAE
References:
Read References with JPT’s Antigen Peptides
NY-ESO 1 89-103, EFYLAMPFATPMEAE has been described in:
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report., J Immunother Cancer, 2020 (PMID: 32913031)
NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma., Cancer Immunol Immunother, 2018 (PMID: 29058035)
Documentation
Documentation for NY-ESO 1 89-103, EFYLAMPFATPMEAE
Properties
Properties of NY-ESO 1 89-103, EFYLAMPFATPMEAE
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Adenocarcinoma, Gastric cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Cancer/testis antigen (NY-ESO) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to NY-ESO 1 89-103, EFYLAMPFATPMEAE
Information | Values |
---|---|
Sequence: | H-EFYLAMPFATPMEAE-OH |
Specifications: | 15mer peptide as TFA salt |